Get Access to Brentuximab vedotin in India

Brentuximab vedotin is a duly approved drug by US FDA and EU EMA. Adcetris is the brand name of this drug which is a research product of Seattle Genetics. This medication is indicated for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The mechanism of action is that of antibody-drug conjugate, selectively targeting malignant cells. Adcetris in India is being imported through Named Patient licensing provisions. Takeda Pharmaceutical Company Limited has the manufacturing and distribution mandate in multiple global locations

The first FDA approval for Brentuximab was granted in the year 2011, which was followed by EMA approval in 2012. They were accelerated approvals. These approvals were also specific to the indications of relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL). Later in 2017 and 2018, the indications for Adcetris were expanded to cutaneous T-cell lymphoma (CTCL), classical Hodgkin lymphoma (cHL) and peripheral T-cell lymphoma (PTCL) with specific eligibility guidelines. Such grants have significantly accelerated the global relevance of this drug and the same is reflective of patients enquiring for Brentuximab in India

Adcetris in India is one of the routine search trends from the major metro cities in the past couple of years. The enquiry pattern from various reputed Hospital networks further confirms its growing importance. Therefore it’s important for patients and even the medicinal fraternity to understand how this drug can be formally procured